- Treatment of relapsing-remitting multiple sclerosis2008 | First Faculty of Medicine
- Ofatumumab - a highly effective therapy for relapsing-remitting multiple sclerosis available in the first line2022 | Faculty of Medicine in Hradec Králové
- Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients2016 | First Faculty of Medicine
- Ocrelizumab - long-term efficacy and safety in real-world clinical practice in patients with relapsing-remitting multiple sclerosis2022 | Second Faculty of Medicine
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study2008 | First Faculty of Medicine
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study2008 | First Faculty of Medicine
- Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis2017 | First Faculty of Medicine
- Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study2016 | First Faculty of Medicine
- Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review2017 | First Faculty of Medicine
- Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis2023 | Faculty of Physical Education and Sport
- Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years : A Longitudinal Study2013 | First Faculty of Medicine
- Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis2014 | First Faculty of Medicine
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | Second Faculty of Medicine
- Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis2021 | Publication without faculty affiliation
- Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase2020 | Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years2020 | First Faculty of Medicine
- Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study2014 | First Faculty of Medicine
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.2008 | Central Library of Charles University
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.2008 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- The Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a double blind active extension of the multicentre, randomised, double-blind, parallel-group placebo-controlled studyPublication without faculty affiliation
- Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis2023 | First Faculty of Medicine, Third Faculty of Medicine
- Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM2015 | First Faculty of Medicine
- Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry2022 | Second Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison2014 | First Faculty of Medicine
- Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study2020 | First Faculty of Medicine
- Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study2014 | First Faculty of Medicine
- Oral BG-12 in relapsing-remitting MS2009 | First Faculty of Medicine
- Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study2010 | First Faculty of Medicine
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | First Faculty of Medicine
- Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis2017 | First Faculty of Medicine